Skandinaviska Enskilda Banken (SEB)
COGT icon

Skandinaviska Enskilda Banken (SEB)’s Cogent Biosciences COGT Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-164,437
Closed -$5.84M – 284
2025
Q4 		$5.84M Buy
+164,437
New +$4.62M 0.02% 386

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s COGT Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 164,437 shares — an estimated $5.84M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in COGT in Q4 2025 and held it in 1 quarter. The position peaked at $5.84M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 164,437 Cogent Biosciences shares in Q1 2026, an estimated $5.84M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Cogent Biosciences in Q4 2025 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Cogent Biosciences position peaked at $5.84M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.